| Popis: |
Abstract Objective The objective of this study was to investigate the effectiveness of testing for active matrix metalloproteinase‐8 (aMMP‐8) by a quantitative point‐of‐care (PoC), chairside lateral flow immunotest and azurocidin, in the peri‐implant sulcular fluid (PISF), as biomarkers for the presence or absence of peri‐implant diseases. Background Current research indicates that proinflammatory cytokines and extracellular matrix‐degrading enzymes may be of value to diagnose and predict peri‐implant disease initiation and progression, but more data are needed. Methods Eighty patients with implants were recruited. PISF samples were collected and quantitatively analyzed for aMMP‐8 (chairside) and azurocidin with ELISA. Radiographic assessments and clinical indices (probing depth, probing attachment level, bleeding on probing, and plaque) were recorded after sampling. Kruskal‐Wallis test and pairwise post hoc Dunn‐Bonferroni test were used to relate aMMP‐8 levels and azurocidin levels to clinical parameters. The diagnostic ability of aMMP‐8 (ng/mL) and azurocidin was analyzed by receiver operator curve analysis. Area under the curve (AUC) was calculated and the Spearman's rho, and the coefficient of determination (R2) were used to calculate the correlations between aMMP‐8, azurocidin, and periodontal parameters. Results Statistically significant differences were observed for aMMP‐8 levels but not for azurocidin between healthy implants, implants with mucositis, and those with peri‐implantitis (13.65 ± 7.18, 32.33 ± 21.20, and 73.07 ± 43.93 ng/mL, respectively), (Kruskall–Wallis test p |
Plný text